Search from website

Cell line development

Leave your inquiry here:

Contact Oliver

Name(Required)

Stable CHO Cell Line
Development — IcoCell

The IcoCell cell line development platform generates stable biopharmaceutical CHO high-producer protein and antibody clones with competitive titers and timelines. It is fully embedded into our integrated in-house discovery and development capabilities, including analytical and downstream processing expertise, effectively speeding up our clients’ clinical development timelines and de-risking their clinical development projects.

Why choose IcoCell for stable GMP compatible cell line?

HIGH
PRODUCTIVITY

HIGH PRODUCTIVITY

Our proven cell line development workflow yields stable biopharmaceutical CHO cell lines with up to 10 g/l production titers for recombinant antibodies and proteins.

RAPID
TIMELINES

RAPID TIMELINES

Our optimized CHO cell line development process yields stable producer clone pools already week after CLD starts.

PURE FEE
FOR SERVICE

PURE FEE FOR SERVICE

No clinical milestone payments, no royalties – only fee for service.

99.9%
MONOCLONAL
ASSURANCE

99.9%
MONOCLONAL
ASSURANCE

In our IcoCell platform we employ the VIPS™ In-Situ Plate Seeding to assure 99.9% monoclonality. The "double lock" method, that combines post cell-dispensing imaging and analysis with daily outgrowth imaging for later regulatory submission.

GMP-
COMPATIBLE
DOCUMENTATION

GMP-
COMPATIBLE
DOCUMENTATION

Full documentation in form of a cell line development report is provided, which is essential for later regulatory submission and GMP manufacturing.

COMPREHENSIVE
ANALYTICS

COMPREHENSIVE ANALYTICS

The IcoCell cell line development approach follows a rigorous analytical regimen with ever-increasing stringency along the way, both on the product and cellular level.

Cell line development workflow with IcoCell

Early non-GMP protein production from stable CHO producer clone pools

A streamlined clone pool selection approach was developed to efficiently generate near-homogenous stable CHO production clone pools with high target protein productivity. These clone pools readily allow gram-scale production runs, plus rapid product characterization, analytical development, formulation development, in vivo POC studies etc. 

COST EFFECTIVE

COST EFFECTIVE AND ROYALTY FREE

We only charge a fee for service.

HIGH TITERS

HIGH TITERS

High titers of recombinant protein is achieved by inserting transgene into transcriptionally active genomic regions.

PROJECT
DE-RISKING

PROJECT DE-RISKING

Early material from stable producer clone pools is the first stage at which one can obtain tangible purified recombinant material that allows an initial peek on the later clone-derived protein. This material can be tested for activity in vitro and even in vivo, and several project-accelerating activities (such as analytical and formulation development) can be started ahead of time.

INITIAL
UPSTREAM
PROCESS
DEVELOPMENT

INITIAL UPSTREAM PROCESS DEVELOPMENT

IcoCell minipools can be used to produce material for early proof of concept and non-GLP tox studies. Also for IVD assays.

EARLY
PROOF OF
CONCEPT

EARLY PROOF OF CONCEPT

Stable producer clone pool titers convey a robust indication of the expected productivities of the final clones, and allow e.g. early proof of concept in vivo in non-GLP toxicology studies, to re-confirm the clinical candidates' potential.

IcoCell workflow for stable high producer clone pool production

Antibody
development
Protein
production
Cell line
development
Analytics

For inquiries about cell line development,
please contact Dr. Oliver Schub

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
error:
Shopping Cart